Precision Diagnosis and Risk Stratification of Rare Cardiomyopathies Based on Novel Cardiac Magnetic Resonance Techniques

What is this study about? This research is focused on improving the care for people with rare heart muscle diseases, known as rare cardiomyopathies. These are uncommon conditions where the heart muscle becomes stiff, thick, or enlarged, making it harder for the heart to pump blood. Because they are rare, they can be difficult to diagnose and manage. The investigators are testing new, advanced ways of using a heart scan called a Cardiac Magnetic Resonance (CMR). Participants can think of a CMR as a very powerful camera that takes detailed pictures of their heart without using radiation. What is the study trying to learn? Better Diagnosis: The investigators want to see if these new scanning techniques can help us identify these rare heart conditions more clearly and accurately. This means patients could get a correct diagnosis sooner. Personalized Risk Assessment: The investigators want to see if the scan can help us understand the future risk for each patient better. For example, can it help predict which patients are more likely to have a heart rhythm problem or need specific treatments? This helps doctors create a care plan that is tailored just for participants. What does this mean for participants? If participants choose to take part, they will undergo a CMR scan that uses these new techniques. By participating, they will be helping us find better ways to diagnose and care for people with their condition in the future. The goal is to turn uncertainty into clearer, more personalized information for patients and families.

NCT Number	NCT07336394
Lead Sponsor	Chinese Academy of Medical Sciences, Fuwai Hospital Collaborators: Peking Union Medical College Hospital, Beijing Anzhen Hospital, The First Affiliated Hospital with Nanjing Medical University
Conditions	Danon Disease, Fabry Disease, Cardiac Amyloidosis, Noonan Syndrome, Cardiac Sarcoidosis, Glycogen Storage Disease, Idiopathic Cardiomyopathy
Enrollment	1,000 participants
Start Date	2010-01-01
Primary Completion	2028-12-30 (estimated)
Study Completion	2030-12-30 (estimated)
Updated on ClinicalTrials.gov	2026-01-21